Original Resear	Volume-8 Issue-10 October-2018 PRINT ISSN No 2249-555X Biochemistry EVALUATION OF TG/HDL CHOLESTEROL RATIO AND NON HDL/HDL RATIO AS A MARKER OF CARDIOVASCULAR RISK IN DIABETICS MELLITUS
Sunita D. Singh	Demonstrator Department of Biochemistry Government Doon Medical College, Dehradun
Nita Garg*	Professor & Head Department of Biochemistry SGRRIM&HS, Dehradun

*Corresponding Author

ABSTRACT] Aim: The aim of our study was to determine lipid profile levels in diabetics and nondiabetics and to evaluate cardiovascular risk using TG/HDLc ratio and Non HDLc/HDLc ratios.

Study Design: A hospital based cross sectional study was conducted on patients attending the Out Patient Department of Medicine of Doon Medical College, Dehradun (Uttarakhand) during a period of 06 months from January 2018 to June 2018. 200 patients (100 Diabetics + 100 Nondiabetics) in the age group 30-80 years were selected randomly for the study. Of the 100 Diabetics (52 Male + 48 Female) and of the 100 Non diabetics 56 were males and 44 were females. All the participants underwent biochemical analysis-FBS, PPBS, HbA1C and lipid profile (TC, TG, HDL), LDL, VLDL and Non-HDL were calculated by computational methods. TG/HDLc ratio and Non HDLc/HDLc ratios were also calculated to assess cardiovascular risk.

Methodology: Biochemical & statistical analysis was done on all the selected 200 subjects. TG/HDL ratio and Non-HDLc/HDLc ratios were calculated.

Results: Total Cholesterol, TG, LDL & TG/HDLc ratio & Non-HDL/HDL ratio were found to be significantly increased in diabetics when compared with non diabetics. HDL levels were found to be & slightly less in diabetics as compared to Non diabetics.

Conclusion: We concluded that Non HDlc/HDLc ratio & TG/HDLc ratio can be used as early markers of cardiovascular risk.

KEYWORDS: Diabetes Mellitus, Non HDLc, TG/HDLc ratio, Non-HDLc /HDlc ratio.

INTRODUCTION:

Type 2 Diabetes Mellitus is a part of the metabolic syndrome with a cluster of several abnormalities, including insulin resistance, dyslipidaemia and cardiovascular disease^(1,2), which in part might be due to abnormalities in lipid & lipoprotein metabolism^(3,4).

Type 2 diabetes and its complications lead to an elevated cardiovascular risk globally. Adults with diabetes have 2 to 4 times higher risk of experiencing cardiovascular events than adults with no diabetes(5,6).

It has also been suggested that non-HDLc may be a strong predictor of coronary heart disease mortality and non-fatal coronary events than LDL-c in people with diabetes⁽⁴⁾. Elevated non HDLc signifies increase in cardiovascular risk even if LDLc levels are at or below the NCEP goal or appear to be normal⁽⁷⁾.

The aim of the present study was to compile further evidence for clinical utility of TG/HDlc ratio & Non HDLc/HDLc ratio as a simple & effective tool for early identification of cardiovascular disease.

METHODOLOGY: A hospital based cross sectional study was conducted on patients attending the Out Patient Department of Medicine of Doon Medical College, Dehradun (Uttarakhand) during a period of 06 months from January 2018 to June 2018. 200 patients (100


Diabetics + 100 Non-diabetics) in the age group 30-80 years were selected randomly for the study. Of the 100 Diabetics (52 Male + 48 Female) and of the 100 Non diabetics 56 were males and 44 were females. All the participants underwent biochemical analysis-FBS, PPBS, HbA1C and lipid profile (TC, TG, HDL), LDL, VLDL and Non-HDL were calculated by computational methods. TG/HDLc ratio and Non HDLc/HDLc ratios were also calculated to assess cardiovascular risk.

Fasting blood sugar was estimated using glucose oxidase method⁽⁸⁾ Total cholesterol & HDLc were determined by enzymatic methods^(9,10). TG was estimated by an analytical method based on the sequence of reactions described by Fossatic et al(11). LDLc was calculated according to the computational procedures of Freidwald et al⁽¹³⁾. Statistical analysis was done using SPSS software and values were expressed as mean±SD±SE.

RESULTS: Total Cholesterol, TG, LDL & TG/HDLc ratio & Non-HDLc/HDLc ratio were found to be significantly increased in diabetics when compared with nondiabetics. HDLc levels were found to be & slightly less in diabetics as compared to Nondiabetics. Non-HDLc/HDLc ratio and TG/ HDLc ratio were significantly raised as compared to nondiabetics. The observations are tabulated in Table 1 and depicted graphically in Figure 1.

Parameters	Diabetic (52 male + 48 female) mean±SD±SE	Non-diabetic (52 male + 48 female) mean±SD±SE	t- value	p- value	Significant
FBS mg/dl	196±74.79±10.32	92.8±14.85±2.05	9.57	< 0.0001	HS
PPBS mg/dl	300±80.99±11.77	150.72±34. 19±4.72	12.005	< 0.0001	HS
HBA1C	9.81±2.58±0.36	5.53±1.20±0.17	10.62	< 0.0001	HS
TC mg/dl	221.08±55.51±7.66	192.54±49.68±6.85	2.7	0.008	HS
TG mg/dl	253.44±142.58±19.67	194.76±118 21±16.30	2.24	0.02	S
HDLc	40.84±8.17±1.13	41.18±3.96±0.55	-0.2	0.76	NS
LDLc	129.53±46.93±6.47	115.28±37.60±.19	1.68	0.09	NS
Non HDLc	180.24±55.8±7.7	151.36±49.71±6.86	2.73	0.007	HS
TG/HDLc	6.54±4.38±0.60	4.89±3.34±0.46	2.11	0.03	S
NonHDLc/HDLc	4.58±1.76±0.24	3.72±1.32±0.46	2.76	0.006	HS

INDIAN JOURNAL OF APPLIED RESEARCH



DISCUSSION:

Cardiovascular vascular disease is the primary cause of morbidity and mortality in patients with diabetes and accounts for approx 65% of overall death with diabetic complications. Adults with diabetes have approx two to four times higher CVD rate than adults without diabetes⁽¹³⁾. Type 2 Diabetes is also frequently associated with vascular complications & dyslipidemia. The major features initially recognized were hypertriglyceridemia, decreased levels of HDLc and a normal or elevated levels of LDLc with an altered composition.

The present study showed 54% of the diabetics to be hypercholesterolaemic (TC≥ 200mg/dl), which is in consistent with the study by Sert et al⁽¹⁵⁾. Our study showed 64% of diabetics had hypertriglyceridemia (TG≥150mg/dl) and it is also support by studies by Sert et al⁽¹⁵⁾ & Regmi et al⁽¹⁶⁾. Our study also reveals 64% of diabetic patients had serum LDLc≥100mg/dl, a similar study by Turkey reported that 69.1% of diabetics had serum LDLc≥100mg/dl⁽¹⁵⁾. Our study depicted 60% of diabetics with HDLc less than 40mg/dl which is in accordance with the study by A. Pandeya⁽¹⁷⁾.

Non-HDLc is a single index of all the atherogenic apolipoprotein B containing lipoproteins LDL, VLDL, IDL. Hence in patients with diabetes, non-HDLc may be a stronger predictor of cardiovascular disease than either LDLc or TG. NCEP guidelines state that the LDLc is not a valid basis for therapeutic decision when TG level is above 200mg/dl, instead Non-HDLc is the therapeutic target⁽¹⁸⁾. So Non-HDLc, the elevated level of which signifies increased CVD risk, can be used as part of lipid profile.

Our study suggests that TG/HDLc ratio & Non-HDLc/HDLc ratio can be used as markers for insulin resistance and CVD risk in Type 2 diabetes patients(19).

CONCLUSION: We conclude that Diabetes mellitus and dyslipidaemia go hand in hand. Dyslipidemia ia an independent risk factor for cardiovascular diseases. Non-HDLc/HDLc ratio and TG/ HDLc ratio can be used as simple, cumulative & early markers of cardiovascular diseases. They are cost effective, available and affordable markers of cardiovascular risks.

REFERENCES

- Meigs JB. Epidemiology of the metabolic syndrome Am J manag Care 2002; 8(11 1. supply): S283-92; quiz S293-96.
- 2. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
- 3 Syvanne M, Taskinen M-R. Lipids and Lipo-proteins as coronary risk factors in noninsulin dependent Diabetes mellitus Lancet 1997:350(S1): S20-3.
- 4. Stamler J. Vaccaro O. Neaton JD et al. Diabetes other risk factors, and 12 year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44.
- Fox CS, Coady S, Sorlic PD et al. Trends in cardiovascular complications of diabetics. J. Amer Med Assoc 2004;292:2495-499.
- 6 Laakso M. Cardiovascular disease in type-2 diabetes challenge for treatment and prevention, J. Intern Med 2001:249:225-35 Garg A, Grundy SM Management of dyslipidemia in NIDDM. Diabetes Care 7.
- 1990;13:153-69 Huggett A.S. Nixon DA; use of glucose oxidase, peroxidase, & O-dianisidine in
- determination of blood & urinary glucose Lancet 1957;273:368-70 (pubmed). 9
- Allain C.C., Poon L.S. ; Chan C.S. et al. enzymatic determination of total serum cholesterol. Clin Chem. 1974;20:470-75 (pubmed). 10 Burstein M; Scholnick H.R, Morfin R. Rapid method for isolation of lipoprotein from
- human serum by precipitation with polyanion. J lipid Res. 1970;11:583-95 (pubmed).

- 11. Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produce Hydrogen peroxide. Clin Chem. 1982;28:2077-80(pubmed).
- Friedwald Wi, Levy R.I, Fredrickson D.S. Estimation of the concentration of LDL 12. cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502(pubmed).
- American Diabetes Association website: Complication of Diabetes mellitus in United 13. States. Availabe at www. Diabetes.org/diabetes-statistics/complications/jsp.Accessed January 29.2011
- Wilson PW, Kannel WB, Anderson KM, Linids, glucose intolerance and vascular 14 diseases: the Framingham study. Monogr Atheroscler 1985;13:1-11.
- Sert M, Morgul G, Tetiker BT. Diabetic dyslipidema is a well known issue, but what 15. about lipoprotein a levels in Type 2 diabetics? Int 'I J Diabetes Metab 2010;18:81-7
- Regmi P, Gyawali P, Shrestha R, et al. Pattern of dyslipidemia in Type II Diabetic subjects in Eestern Nepal, JNAMLS 2009:10:11-13. 16
- 17 Pandeva A, Sharma M, Ragni P et al. Pattern of dyslipidemia and evaluation of non HDL-Cholesterol as a marker of risk factor for cardiovascular disease in type-2 diabetes Mellitus. Nepal Med Coll J 2012;14(4):278-282
- 18 Executive summary of the third Report of the National Cholesterol Education Programme (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J Amer Med Assoc 2001:285:2486-97.
- Stampfer MJ, Sacks FM, Salvini S, Willett WC et al. A perspective study of cholesterol, 19. apolioprotiens, and the risk of myocardial infarction. N Engl J Med 1991;325:373-81.

25